SIRT3 deregulation is linked to mitochondrial dysfunction in Alzheimer's disease

Aging Cell

Volumn 17, Issue 1, 2018, Pages

  Lee, Junghee ^a,b   Kim, Yunha ^c   Liu, Tian ^c,h   Hwang, Yu Jin ^c   Hyeon, Seung Jae ^c   Im, Hyeonjoo ^c   Lee, Kyungeun ^c   Alvarez, Victor E ^b,d   McKee, Ann C ^a,b   Um, Soo Jong ^e   Hur, Manwook ^f   Mook Jung, Inhee ^g   Kowall, Neil W ^a,b   Ryu, Hoon ^a,b,c  

^a VA BOSTON HEALTHCARE SYSTEM   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Korea Institute of Science and Technology   (South Korea)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e Sejong University   (South Korea)

^f Yonsei University College of Medicine   (South Korea)

^g Seoul National University College of Medicine   (South Korea)

^h UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Alzheimer's disease; gene expression; mitochondria; p53; SIRT3

Indexed keywords

CASPASE 3; CYTOCHROME C; DOXYCYCLINE; HISTONE DEACETYLASE; MESSENGER RNA; MITOCHONDRIAL DNA; ND2 PROTEIN; ND4 PROTEIN; PROTEIN P53; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); RNA 12S; SIRTUIN 3; UNCLASSIFIED DRUG; SIRT3 PROTEIN, HUMAN; SIRT3 PROTEIN, MOUSE; SIRTUIN; TP53 PROTEIN, HUMAN; TRP53 PROTEIN, MOUSE;

ALZHEIMER DISEASE; ANIMAL CELL; ARTICLE; BRAIN CORTEX; CONTROLLED STUDY; DISEASE ASSOCIATION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DNA FRAGMENTATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; MITOCHONDRIAL GENOME; MITOCHONDRIAL MEMBRANE; MITOCHONDRION; NERVE CELL; NERVE INJURY; NEUROMODULATION; NONHUMAN; OXYGEN CONSUMPTION; PERMEABILITY; PRIORITY JOURNAL; PROTEIN ANALYSIS; ANIMAL; DRUG EFFECT; METABOLISM; MOUSE; OXIDATIVE STRESS; PATHOLOGY;

ALZHEIMER DISEASE; ANIMALS; MICE; MITOCHONDRIA; NEURONS; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; SIRTUIN 3; SIRTUINS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 85033592642     PISSN: 14749718     EISSN: 14749726     Source Type: Journal    
DOI: 10.1111/acel.12679     Document Type: Article

References (57)

1. Achanta G, Huang P (2004) Role of p53 in sensing oxidative DNA damage in response to reactive oxygen species-generating agents. Cancer Res. 64, 6233–6239.
2. Achanta G, Sasaki R, Feng L, Carew JS, Lu W, Pelicano H, Keating MJ, Huang P (2005) Novel role of p53 in maintaining mitochondrial genetic stability through interaction with DNA Pol gamma. EMBO J. 24, 3482–3492.
3. Barja G (2007) Mitochondrial oxygen consumption and reactive oxygen species production are independently modulated: implications for aging studies. Rejuvenation Res. 10, 215–224.
4. Barone E, Cenini G, Sultana R, Di Domenico F, Fiorini A, Perluigi M, Noel T, Wang C, Mancuso C, St Clair DK, Butterfield DA (2012) Lack of p53 decreases basal oxidative stress levels in the brain through upregulation of thioredoxin-1, biliverdin reductase-A, manganese superoxide dismutase, and nuclear factor kappa-B. Antioxid. Redox Signal. 16, 1407–1420.
5. Bergeaud M, Mathieu L, Guillaume A, Moll UM, Mignotte B, Le Floch N, Vayssiere JL, Rincheval V (2013) Mitochondrial p53 mediates a transcription-independent regulation of cell respiration and interacts with the mitochondrial F(1)F0-ATP synthase. Cell Cycle 12, 2781–2793.
6. Bonilla E, Tanji K, Hirano M, Vu TH, DiMauro S, Schon EA (1999) Mitochondrial involvement in Alzheimer's disease. Biochim. Biophys. Acta 1410, 171–182.
7. Brandl A, Wagner T, Uhlig KM, Knauer SK, Stauber RH, Melchior F, Schneider G, Heinzel T, Kramer OH (2012) Dynamically regulated sumoylation of HDAC2 controls p53 deacetylation and restricts apoptosis following genotoxic stress. J. Mol. Cell Biol. 4, 284–293.
8. Brandt U (2006) Energy converting NADH:quinone oxidoreductase (complex I). Annu. Rev. Biochem. 75, 69–92.
9. Canter RG, Penney J, Tsai LH (2016) The road to restoring neural circuits for the treatment of Alzheimer's disease. Nature 539, 187–196.
10. Chandrasekaran K, Hatanpaa K, Brady DR, Rapoport SI (1996) Evidence for physiological down-regulation of brain oxidative phosphorylation in Alzheimer's disease. Exp. Neurol. 142, 80–88.
11. Coyle JT, Price DL, DeLong MR (1983) Alzheimer's disease: a disorder of cortical cholinergic innervation. Science 21, 1184–1190.
12. Erster S, Moll UM (2004) Stress-induced p53 runs a direct mitochondrial death program: its role in physiologic and pathophysiologic stress responses in vivo. Cell Cycle 3, 1492–1495.
13. Favret KP, Lynn JW (2010) Flow-cytometric analyses of viability biomarkers in pesticide-exposed sperm of three aquatic invertebrates. Arch. Environ. Contam. Toxicol. 58, 973–984.
14. Fiorini A, Sultana R, Barone E, Cenini G, Perluigi M, Mancuso C, Cai J, Klein JB, St Clair D, Butterfield DA (2012) Lack of p53 affects the expression of several brain mitochondrial proteins: insights from proteomics into important pathways regulated by p53. PLoS ONE 7, e49846.
15. Follis AV, Llambi F, Ou L, Baran K, Green DR, Kriwacki RW (2014) The DNA-binding domain mediates both nuclear and cytosolic functions of p53. Nat. Struct. Mol. Biol. 21, 535–543.
16. Fukuyama R, Hatanpaa K, Rapoport SI, Chandrasekaran K (1996) Gene expression of ND4, a subunit of complex I of oxidative phosphorylation in mitochondria, is decreased in temporal cortex of brains of Alzheimer's disease patients. Brain Res. 713, 290–293.
17. Hagen G, Dennig J, Preiss A, Beato M, Suske G (1995) Functional analyses of the transcription factor Sp4 reveal properties distinct from Sp1 and Sp3. J. Biol. Chem. 270, 24989–24994.
18. Hayashi T, Stuchebrukhov AA (2010) Electron tunneling in respiratory complex I. Proc. Natl Acad. Sci. USA 107, 19157–19162.
19. Heyne K, Mannebach S, Wuertz E, Knaup KX, Mahyar-Roemer M, Roemer K (2004) Identification of a putative p53 binding sequence within the human mitochondrial genome. FEBS Lett. 578, 198–202.
20. Hirschey MD, Shimazu T, Goetzman E, Jing E, Schwer B, Lombard DB, Grueter CA, Harris C, Biddinger S, Ilkayeva OR, Stevens RD, Li Y, Saha AK, Ruderman NB, Bain JR, Newgard CB, Farese RV Jr, Alt FW, Kahn CR, Verdin E (2010) SIRT3 regulates mitochondrial fatty-acid oxidation by reversible enzyme deacetylation. Nature 464, 121–125.
21. Hooper C, Meimaridou E, Tavassoli M, Melino G, Lovestone S, Killick R (2007) p53 is upregulated in Alzheimer's disease and induces tau phosphorylation in HEK293a cells. Neurosci. Lett. 418, 34–37.
22. Hoshino A, Mita Y, Okawa Y, Ariyoshi M, Iwai-Kanai E, Ueyama T, Ikeda K, Ogata T, Matoba S (2013) Cytosolic p53 inhibits Parkin-mediated mitophagy and promotes mitochondrial dysfunction in the mouse heart. Nat. Commun. 4, 2308.
23. Ito A, Lai CH, Zhao X, Saito S, Hamilton MH, Appella E, Yao TP (2001) p300/CBP-mediated p53 acetylation is commonly induced by p53-activating agents and inhibited by MDM2. EMBO J. 20, 1331–1340.
24. Kim D, Nguyen MD, Dobbin MM, Fischer A, Sananbenesi F, Rodgers JT, Delalle I, Baur JA, Sui G, Armour SM, Puigserver P, Sinclair DA, Tsai LH (2007) SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer's disease and amyotrophic lateral sclerosis. EMBO J. 26, 3169–3179.
25. Kim HS, Patel K, Muldoon-Jacobs K, Bisht KS, Aykin-Burns N, Pennington JD, van der Meer R, Nguyen P, Savage J, Owens KM, Vassilopoulos A, Ozden O, Park SH, Singh KK, Abdulkadir SA, Spitz DR, Deng CX, Gius D (2010) SIRT3 is a mitochondria-localized tumor suppressor required for maintenance of mitochondrial integrity and metabolism during stress. Cancer Cell 17, 41–52.
26. Kim SH, Lu HF, Alano CC (2011) Neuronal Sirt3 protects against excitotoxic injury in mouse cortical neuron culture. PLoS ONE 6, e14731.
27. Koh DI, Han D, Ryu H, Choi WI, Jeon BN, Kim MK, Kim Y, Kim JY, Parry L, Clarke AR, Reynolds AB, Hur MW (2014) KAISO, a critical regulator of p53-mediated transcription of CDKN1A and apoptotic genes. Proc. Natl Acad. Sci. USA 111, 15078–15083.
28. Kushnareva Y, Murphy AN, Andreyev A (2002) Complex I mediated reactive oxygen species generation: modulation by cytochrome c and NAD(P) oxidation-reduction state. Biochem J. 368, 545–553.
29. Lee J, Ryu H (2010) Epigenetic modification is linked to Alzheimer's disease: is it a maker or a marker? BMB Rep. 43, 649–655.
30. Lee J, Kim CH, Simon D, Aminova L, Andreyev A, Kushnareva Y, Murphy A, Lonze BE, Kim KS, Ginty DD, Ferrante RJ, Ryu H, Ratan RR (2005) Mitochondrial CREB regulates mitochondrial gene expression and neuronal survival. J. Biol. Chem. 280, 40398–40401.
31. Li S, Banck M, Mujtaba S, Zhou MM, Sugrue MM, Walsh MJ (2010) p53-induced growth arrest is regulated by the mitochondrial SirT3 deacetylase. PLoS ONE 5, e10486.
32. Mahyar-Roemer M, Fritzsche C, Wagner S, Laue M, Roemer K (2004) Mitochondrial p53 levels parallel total p53 levels independent of stress response in human colorectal carcinoma and glioblastoma cells. Oncogene 23, 6226–6236.
33. Marchenko ND, Zaika A, Moll UM (2000) Death signal-induced localization of p53 protein to mitochondria. A potential role in apoptotic signaling. J. Biol. Chem. 275, 16202–16212.
34. Mathiesen C, Hagerhall C (2002) Transmembrane topology of the NuoL, M and N subunits of NADH:quinone oxidoreductase and their homologues among membrane-bound hydrogenases and bona fide antiporters. Biochim. Biophys. Acta 1556, 121–132.
35. Mihara M, Erster S, Zaika A, Petrenko O, Chittenden T, Pancoska P, Moll UM (2003) p53 has a direct apoptogenic role at the mitochondria. Mol. Cell 11, 577–590.
36. Moll UM, Wolff S, Speidel D, Deppert W (2005) Transcription-independent pro-apoptotic functions of p53. Curr. Opin. Cell Biol. 17, 631–636.
37. Ohyagi Y, Asahara H, Chui DH, Tsuruta Y, Sakae N, Miyoshi K, Yamada T, Kikuchi H, Taniwaki T, Murai H, Ikezoe K, Furuya H, Kawarabayashi T, Shoji M, Checler F, Iwaki T, Makifuchi T, Takeda K, Kira J, Tabira T (2005) Intracellular Abeta42 activates p53 promoter: a pathway to neurodegeneration in Alzheimer's disease. FASEB J. 19, 255–257.
38. Onyango P, Celic I, McCaffery JM, Boeke JD, Feinberg AP (2002) SIRT3, a human SIR2 homologue, is an NAD-dependent deacetylase localized to mitochondria. Proc. Natl Acad. Sci. USA 99, 13653–13658.
39. Palacios G, Crawford HC, Vaseva A, Moll UM (2008) Mitochondrially targeted wild-type p53 induces apoptosis in a solid human tumor xenograft model. Cell Cycle 7, 2584–2590.
40. Park J-H, Li J, Hwang PM (2016) p53 as guardian of the mitochondrial genome. FEBS Lett. 590, 924–934.
41. Roy S, Packman K, Jeffrey R, Tenniswood M (2005) Histone deacetylase inhibitors differentially stabilize acetylated p53 and induce cell cycle arrest or apoptosis in prostate cancer cells. Cell Death Differ. 12, 482–491.
42. Ryu H, Lee J, Impey S, Ratan RR, Ferrante RJ (2005) Antioxidants modulate mitochondrial PKA and increase CREB binding to D-loop DNA of the mitochondrial genome in neurons. Proc. Natl Acad. Sci. USA 102, 13915–13920.
43. Sakaguchi K, Herrera JE, Saito S, Miki T, Bustin M, Vassilev A, Anderson CW, Appella E (1998) DNA damage activates p53 through a phosphorylation-acetylation cascade. Genes Dev. 12, 2831–2841.
44. Sansome C, Zaika A, Marchenko ND, Moll UM (2001) Hypoxia death stimulus induces translocation of p53 protein to mitochondria. Detection by immunofluorescence on whole cells. FEBS Lett. 488, 110–115.
45. Shi T, Wang F, Stieren E, Tong Q (2005) SIRT3, a mitochondrial sirtuin deacetylase, regulates mitochondrial function and thermogenesis in brown adipocytes. J. Biol. Chem. 280, 13560–13567.
46. Silva PN, Gigek CO, Leal MF, Bertolucci PH, de Labio RW, Payao SL, Smith Mde A (2008) Promoter methylation analysis of SIRT3, SMARCA5, HTERT and CDH1 genes in aging and Alzheimer's disease. J. Alzheimers Dis. 13, 173–176.
47. Someya S, Yu W, Hallows WC, Xu J, Vann JM, Leeuwenburgh C, Tanokura M, Denu JM, Prolla TA (2010) Sirt3 mediates reduction of oxidative damage and prevention of age-related hearing loss under caloric restriction. Cell 143, 802–812.
48. Swerdlow RH (2012) Mitochondria and cell bioenergetics: increasingly recognized components and a possible etiologic cause of Alzheimer's disease. Antioxid. Redox Signal. 16, 1434–1455.
49. Teng YD, Choi H, Onario RC, Zhu S, Desilets FC, Lan S, Woodard EJ, Snyder EY, Eichler ME, Friedlander RM (2004) Minocycline inhibits contusion-triggered mitochondrial cytochrome c release and mitigates functional deficits after spinal cord injury. Proc. Natl Acad. Sci. USA 101, 3071–3076.
50. Terui T, Murakami K, Takimoto R, Takahashi M, Takada K, Murakami T, Minami S, Matsunaga T, Takayama T, Kato J, Niitsu Y (2003) Induction of PIG3 and NOXA through acetylation of p53 at 320 and 373 lysine residues as a mechanism for apoptotic cell death by histone deacetylase inhibitors. Cancer Res. 63, 8948–8954.
51. Tomita Y, Marchenko N, Erster S, Nemajerova A, Dehner A, Klein C, Pan H, Kessler H, Pancoska P, Moll UM (2006) WT p53, but not tumor-derived mutants, bind to Bcl2 via the DNA binding domain and induce mitochondrial permeabilization. J. Biol. Chem. 281, 8600–8606.
52. Vaseva AV, Marchenko ND, Ji K, Tsirka SE, Holzmann S, Moll UM (2012) p53 opens the mitochondrial permeability transition pore to trigger necrosis. Cell 149, 1536–1548.
53. Weir HJ, Murray TK, Kehoe PG, Love S, Verdin EM, O'Neill MJ, Lane JD, Balthasar N (2012) CNS SIRT3 expression is altered by reactive oxygen species and in Alzheimer's disease. PLoS ONE 7, e48225.
54. Wolfe MS (2002) Therapeutic strategies for Alzheimer's disease. Nat. Rev Drug Discov. 1, 859–866.
55. Wong TS, Rajagopalan S, Freund SM, Rutherford TJ, Andreeva A, Townsley FM, Petrovich M, Fersht AR (2009) Biophysical characterizations of human mitochondrial transcription factor A and its binding to tumor suppressor p53. Nucleic Acids Res. 37, 6765–6783.
56. Zhao Y, Chaiswing L, Velez JM, Batinic-Haberle I, Colburn NH, Oberley TD, St Clair DK (2005) p53 translocation to mitochondria precedes its nuclear translocation and targets mitochondrial oxidative defense protein-manganese superoxide dismutase. Cancer Res. 65, 3745–3750.
57. Zhuang J, Wang PY, Huang X, Chen X, Kang JG, Hwang PM (2013) Mitochondrial disulfide relay mediates translocation of p53 and partitions its subcellular activity. Proc. Natl Acad. Sci. USA 110, 17356–17361.